Term
| is RCC considered sensitive to XRT? |
|
Definition
| no, but a portion may respond |
|
|
Term
| is there a benefit to XRT in RCC pts post-nephrectomy? |
|
Definition
|
|
Term
| is there a survival advantage to neoadjuvant XRT w/RCC? |
|
Definition
|
|
Term
| does RCC respond to chemotherapy (IFN, medroxyprogesterone-acetate, etc) |
|
Definition
|
|
Term
| what immunotherapy agents are used for RCC management? |
|
Definition
| LAK, IL-2, IF-alpha as well as angiogenesis inhibitors: TKIs/bevacizumab (slight survival benefit) |
|
|
Term
| what is the MOA for sunitinib malate? |
|
Definition
| sunitinib malate inhibits multiple receptor tyrosine kinases which are involved in tumor growth/angiogenesis/metastasis by inhibition of phosphorylation. |
|
|
Term
| who is sunitinib malate used in? |
|
Definition
| pts who failed cytokine therapy see some improvement in objective response rate, but not overall survival |
|
|
Term
| what does pazopanib (and possibly sorafenib) have action on in terms of RCC management? |
|
Definition
| VEGFR1,2,3, PDGFR alpha/beta, and c-kit |
|
|
Term
| *what is early stage prostate CA treatment? |
|
Definition
| radiation or surgery. possibly hormone? |
|
|
Term
| *what is late stage prostate CA treatment? |
|
Definition
| hormone, chemo, radiation |
|
|
Term
| *what are the hormone therapeutic agents used in prostate CA? |
|
Definition
| *GnRH antagonists: lupron, zoladex, eligard, and viadur. *anti-androgens: casodex, eulexin, nilandron (block receptors) |
|
|
Term
| *how long does hormone therapy for prostate CA usually last? |
|
Definition
|
|
Term
| *what is second-line hormone therapy for prostate CA? |
|
Definition
| ketoconazole/prednisone (anti-fungal which blocks adrenal synthesis) |
|
|
Term
| *what is the benefit of mitoxantrone/prednisone (chemo) in prostate CA pts? |
|
Definition
| this drug will make the pt feel better - but not much else |
|
|
Term
| *what ADRs are associated with taxotere (chemo for prostate CA)? how is it administered? |
|
Definition
| ADRs: infections, low white count, anemia, febrile neutropenia, allergic reaction, low platelets, nerve damage, loss of taste, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, myalgia. administered: once a week or once every 3 weeks over an hour. steroids are given before the drug. |
|
|
Term
|
Definition
| an epothilone B analogue: new class of cytotoxic tubulin polymerization agents from fermentation of the broth of myxobacterium sporangium cellulosum |
|
|
Term
| *what are positive prognostic factors for prostate CA? |
|
Definition
| performance status, lack of constitutional symptoms, no wt loss, low ESR, and 0 or 1 metastatic site |
|
|
Term
| *what is tx for penile CA? |
|
Definition
| sx and XRT (chemosensitizing agents) |
|
|
